SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy: A Promising Signal, but Not Yet the Final Word
International Journal of Heart Failure · 2026 · 8 (2) · 169
DOI: 10.36628/ijhf.2026.0045 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Heart Failure, 2026. Verfasst von Darae Kim. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, …. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
ATTR-CM, they examined whether SGLT2i therapy was associated with improved clinical outcomes. Using a propensity score-matched design, they identified 27 treated and 27 untreated patients with balanced baseline characteristics. In this matched cohort, SGLT2i treatment was associated with a significantly lower risk of all-cause mortality. Importantly, the signal remained consistent in sensitivity analyses using treatment as a time-varying covariate, an approach specifically intended to mitigate immortal time bias.
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
ORCID-Profile: Darae Kim
Zitieren
APA
Kim, D. (2026). SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy: A Promising Signal, but Not Yet the Final Word. International Journal of Heart Failure, 8(2), 169. https://doi.org/10.36628/ijhf.2026.0045
Vancouver
Kim D. SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy: A Promising Signal, but Not Yet the Final Word. International Journal of Heart Failure. 2026;8(2):169. doi:10.36628/ijhf.2026.0045
BibTeX
@article{Kim2026,
author = {Kim, Darae},
title = {SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy: A Promising Signal, but Not Yet the Final Word},
journal = {International Journal of Heart Failure},
year = {2026},
volume = {8},
number = {2},
pages = {169},
doi = {10.36628/ijhf.2026.0045}
}
EUVIMED